PPID 2022, 2(3), 9; doi: 10.55636/ppid2030009
Dual Antiretroviral Regimens for HIV—Here to Stay
1 Metro Infectious Disease Consultants, Chicago, IL, USA
2 Howard Brown Health, Chicago, IL, USA
* Corresponding author:
* Author to whom correspondence should be addressed.
Received: 31 May 2022 / Revised: 26 Aug 2022 / Accepted: 20 Jun 2022 / Published: 30 Sep 2022
It has been twenty-five years since antiretroviral therapy (ART) for human immunodeficiency virus (HIV) became available. Treatment has evolved substantially over these decades to become highly effective and produce substantial improvements in morbidity and mortality for people with HIV. The standard of care has been three-drug regimens (3DRs) which include three drugs active against HIV, occasionally with a fourth drug added as a booster agent. Efforts to provide potentially safer or more convenient treatment regimens for people with HIV have served as the impetus to relook at two drug regimens (2DRs). Several studies have led to the establishment of 2DRs as real options for many patients. This review summarizes clinical data for the established 2DRs and explores some of the remaining questions and concerns about these regimens.
Keywords: Human Immunodeficiency Virus (HIV); antiretroviral therapy (ART); two-drug regimen
This is an open access article distributed under the Creative Commons Attribution License which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited. (CC BY 4.0).
Creticos, C. Dual Antiretroviral Regimens for HIV—Here to Stay. private_pract_infectious_disease 2022, 2, 9.
Creticos C. Dual Antiretroviral Regimens for HIV—Here to Stay. Private Practice Infectious Disease. 2022; 2(3):9.
Creticos, Catherine. 2022. "Dual Antiretroviral Regimens for HIV—Here to Stay." private_pract_infectious_disease 2, no. 3: 9.